Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs

详细信息    查看全文

• 作者：Gerard L. Brien¹ ; ² ; Daria G. Valerio¹ ; ² ; Scott A. Armstrong¹ ; ² ; ³ ; ^{armstros@mskcc.org" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Cancer ; epigenome ; targeted therapy ; chromatin ; histone modification
• 刊名：Cancer Cell
• 出版年：2016
• 出版时间：11 April 2016
• 年：2016
• 卷：29
• 期：4
• 页码：464-476
• 全文大小：1372 K

文摘

The epigenome is a key determinant of transcriptional output. Perturbations within the epigenome are thought to be a key feature of many, perhaps all cancers, and it is now clear that epigenetic changes are instrumental in cancer development. The inherent reversibility of these changes makes them attractive targets for therapeutic manipulation, and a number of small molecules targeting chromatin-based mechanisms are currently in clinical trials. In this perspective we discuss how understanding the cancer epigenome is providing insights into disease pathogenesis and informing drug development. We also highlight additional opportunities to further unlock the therapeutic potential within the cancer epigenome.